everolimus

The addition of everolimus, a mammalian target of rapamycin inhibitor, to octreotide marginally improves the 6-month progression-free survival (PFS) rate...We present the first case of a refractory meningioma patient treated with combination PRRT and octreotide in a 66-year-old male who received 177Lu-DOTATATE 7.4 GBq (200 mCi) and intramuscular long-acting octreotide 40 mg every 8 weeks for four cycles followed by a single cycle of octreotide 40 mg monotherapy...A 7-week post-treatment MRI brain demonstrated stable disease with 11.5% reduction per RANO-Meningioma and a 2.6% reduction per RECIST 1.1 criteria. Combined PRRT and octreotide represents a promising therapeutic strategy for patients with refractory meningioma.

This premilinary in vitro data suggest a trend toward ibrutinib resistance in Oxphos-type cell lines. More research is warranted both in preclinical models as well as in clinical datasets.

P2, N=53, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Jan 2026 --> Jan 2027

P1, N=31, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

Treatment paradigms have advanced from non-targeted options, such as fulvestrant monotherapy or everolimus-based combinations, to precision medicine strategies, including inhibitors of the PI3K/AKT pathway, oral selective estrogen receptor degraders (SERDs), and novel ER-modulating agents, often guided by biomarkers and molecular surveillance... Early second-line standards, including fulvestrant and alpelisib for PIK3CA-mutated tumors, established the basis for biomarker-guided treatment in hormone receptor-positive, HER2-negative metastatic breast cancer...Elacestrant improved progression-free survival in ESR1-mutated disease in the EMERALD trial, capivasertib plus fulvestrant demonstrated significant benefit in tumors harboring AKT/PIK3CA/PTEN pathway alterations in CAPItello-291, and inavolisib plus palbociclib and fulvestrant achieved both progression-free and overall survival improvement in PIK3CA-mutated patients with early relapse in INAVO120... Post-CDK4/6i management increasingly relies on NGS-guided precision approaches, integrating pathway-specific therapies and ctDNA surveillance to tailor sequencing based on resistance profiles, prior ET response, and tumor heterogeneity. Future investigations into novel ER degraders and multi-targeted combinations hold potential to further optimize algorithms, extend non-chemotherapy options, and enhance survival in HR+/HER2- mBC.

P2, N=120, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

These findings demonstrate that mTORi with everolimus reverses multiple mechanisms of immune resistance in TP53 -mutant HNSCC by promoting immune cell recruitment, suppressing immunosuppressive pathways, and enhancing anti-tumor T cell activity. Collectively, these results support mTORi as a mechanistically rational strategy for reprogramming immune resistance in TP53 -mutant HNSCC and provide a strong preclinical rationale for combining everolimus with immune therapy in patients who are likely to fail immunotherapy.

The mTOR inhibitor Everolimus effectively suppressed tumour growth in an EF-colonied orthotopic model, highlighting its therapeutic potential for HCC patients with high EF burden. Collectively, this work establishes a causal link between tumour-resident E. faecalis and hepatocarcinogenesis, revealing EF-Obg as a cross-kingdom activator of mTOR and providing a rationale for microbiota-guided personalised therapy in HCC.

Altogether, these findings indicate that J4 modulates oligodendroglial lineage populations, enhances myelination, and improves neural connectivity by regulating neuronal hyperactivity. Our results suggest that J4 is a strong therapeutic candidate for addressing the neuropsychiatric manifestations of TSC.

P1, N=50, Recruiting, University of California, San Francisco | Suspended --> Recruiting

P3, N=88, Completed, Centre Hospitalier Universitaire, Amiens | Unknown status --> Completed

CNI minimization - through basiliximab induction, low-dose tacrolimus with mycophenolate, or everolimus conversion - improves renal outcomes without compromising graft survival, despite trade-offs such as mild acute rejection or higher malignancy rates. Muñoz-Serrano et al retrospectively analyzed 594 liver transplant recipients over three decades to identify risk factors for CKD at one year post-transplant. The authors identified older age, female sex, pre-transplant renal dysfunction, and treatment with cyclosporine A as independent risk factors.